Follistatin‑like protein 1 knockdown elicits human gastric cancer cell apoptosis via a STAT6‑dependent pathway

Peng,Xingang; Wang,Peige; Li,Shikuan; Jiang,Yingjun; Wu,Changliang

doi:10.3892/or.2019.7334

Follistatin‑like protein 1 knockdown elicits human gastric cancer cell apoptosis via a STAT6‑dependent pathway

Authors:
- Xingang Peng
- Peige Wang
- Shikuan Li
- Yingjun Jiang
- Changliang Wu
View Affiliations

Affiliations: Department of General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Emergency General Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266555, P.R. China
Published online on: September 24, 2019 https://doi.org/10.3892/or.2019.7334
Pages: 2806-2813

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is an aggressive disease and a common cause of cancer‑associated mortality worldwide. Recent studies have indicated that follistatin‑like protein 1 (FSTL‑1) is expressed and serves essential roles in tumorigenesis; however, the specific functional mechanism of FSTL‑1 in gastric cancer progression remains ambiguous. CellTiter‑Glo Luminescent Cell Viability and lactate dehydrogenase assays were used to measure cell survival and cell cytotoxicity, respectively. Cell apoptosis was ascertained using the Cell Death Detection ELISA assay and caspase‑3/9 activity kits. Reverse transcription‑quantitative polymerase chain reaction and western blotting were used to detect the expression levels of FSTL‑1. The present study confirmed that FSTL‑1 was highly expressed in gastric cancer cells compared with in control cells. Subsequently, FSTL‑1 inhibition by small interfering RNA significantly reduced cancer cell survival and induced cytotoxic effects. In addition, knockdown of FSTL‑1 in gastric cancer cells promoted apoptosis by increasing caspase‑3 and caspase‑9 expression. A decrease in signal transducer and activator of transcription 6 (STAT6) phosphorylation was observed in FSTL‑1 knockdown cells, and the results confirmed that STAT6 phosphorylation was essential for FSTL‑1 knockdown‑induced cell apoptosis of cancer cells. Taken together, these results demonstrated that FSTL‑1 knockdown may promote cell apoptosis via the STAT6 signaling pathway; therefore, FSTL1 may be considered a novel diagnostic and therapeutic target for gastric cancer.

View Figures

View References

1	Kim H, Eun JW, Lee H, Nam SW, Rhee H, Koh KH and Kim H: Gene expression changes in patient-matched gastric normal mucosa, adenomas, and carcinomas. Exp Mol Pathol. 90:201–209. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
3	Togo R, Ishihara K, Mabe K, Oizumi H, Ogawa T, Kato M, Sakamoto N, Nakajima S, Asaka M and Haseyama M: Preliminary study of automatic gastric cancer risk classification from photofluorography. World J Gastrointest Oncol. 10:62–70. 2018. View Article : Google Scholar : PubMed/NCBI
4	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
5	De Manzoni G, Marrelli D, Baiocchi GL, Morgagni P, Saragoni L, Degiuli M, Donini A, Fumagalli U, Mazzei MA, Pacelli F, et al: The Italian research group for gastric cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer. 20:20–30. 2017. View Article : Google Scholar : PubMed/NCBI
6	Brenner H: Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet. 360:1131–1135. 2002. View Article : Google Scholar : PubMed/NCBI
7	Werner M, Becker KF, Keller G and Höfler H: Gastric adenocarcinoma: Pathomorphology and molecular pathology. J Cancer Res Clin Oncol. 127:207–216. 2001. View Article : Google Scholar : PubMed/NCBI
8	Tahara E: Genetic pathways of two types of gastric cancer. IARC Sci Publ. 157:327–349. 2004.
9	Wei Q, Wang YN, Liu HY, Yang J, Yang CY, Liu M, Liu YF, Yang P and Liu ZH: The expression and role of activin A and follistatin in heart failure rats after myocardial infarction. Int J Cardiol. 168:2994–2997. 2013. View Article : Google Scholar : PubMed/NCBI
10	Shibanuma M, Mashimo J, Mita A, Kuroki T and Nose K: Cloning from a mouse osteoblastic cell line of a set of transforming-growth-factor-beta 1-regulated genes, one of which seems to encode a follistatin-related polypeptide. Eur J Biochem. 217:13–19. 1993. View Article : Google Scholar : PubMed/NCBI
11	Sylva M, Moorman AF and van den Hoff MJ: Follistatin-like 1 in vertebrate development. Birth Defects Res C Embryo Today. 99:61–69. 2013. View Article : Google Scholar : PubMed/NCBI
12	Prakash S, Borreguero LJJ, Sylva M, Flores Ruiz L, Rezai F, Gunst QD, de la Pompa JL, Ruijter JM and van den Hoff MJB: Deletion of Fstl1 (follistatin-like 1) from the endocardial/endothelial lineage causes mitral valve disease. Arterioscler Thromb Vasc Biol. 37:e116–e130. 2017. View Article : Google Scholar : PubMed/NCBI
13	Kawabata D, Tanaka M, Fujii T, Umehara H, Fujita Y, Yoshifuji H, Mimori T and Ozaki S: Ameliorative effects of follistatin-related protein/TSC-36/FSTL1 on joint inflammation in a mouse model of arthritis. Arthritis Rheum. 50:660–668. 2004. View Article : Google Scholar : PubMed/NCBI
14	Miyamae T, Marinov AD, Sowders D, Wilson DC, Devlin J, Boudreau R, Robbins P and Hirsch R: Follistatin-like protein-1 is a novel proinflammatory molecule. J Immunol. 177:4758–4762. 2006. View Article : Google Scholar : PubMed/NCBI
15	Bae K, Park KE, Han J, Kim J, Kim K and Yoon KA: Mitotic cell death caused by follistatin-like 1 inhibition is associated with up-regulated Bim by inactivated Erk1/2 in human lung cancer cells. Oncotarget. 7:18076–18084. 2016. View Article : Google Scholar : PubMed/NCBI
16	Dong Y, Geng Y, Li L, Li X, Yan X, Fang Y, Li X, Dong S, Liu X, Li X, et al: Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice. J Exp Med. 212:235–252. 2015. View Article : Google Scholar : PubMed/NCBI
17	Ouchi N, Oshima Y, Ohashi K, Higuchi A, Ikegami C, Izumiya Y and Walsh K: Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem. 283:32802–32811. 2008. View Article : Google Scholar : PubMed/NCBI
18	Geng Y, Dong Y, Yu M, Zhang L, Yan X, Sun J, Qiao L, Geng H, Nakajima M, Furuichi T, et al: Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development. Proc Natl Acad Sci USA. 108:7058–7063. 2011. View Article : Google Scholar : PubMed/NCBI
19	Sylva M, Li VS, Buffing AA, van Es JH, van den Born M, van der Velden S, Gunst Q, Koolstra JH, Moorman AF, Clevers H and van den Hoff MJ: The BMP antagonist follistatin-like 1 is required for skeletal and lung organogenesis. PLoS One. 6:e226162011. View Article : Google Scholar : PubMed/NCBI
20	Xu J, Qi X, Gong J, Yu M, Zhang F, Sha H and Gao X: Fstl1 antagonizes BMP signaling and regulates ureter development. PLoS One. 7:e325542012. View Article : Google Scholar : PubMed/NCBI
21	Murakami K, Tanaka M, Usui T, Kawabata D, Shiomi A, Iguchi-Hashimoto M, Shimizu M, Yukawa N, Yoshifuji H, Nojima T, et al: Follistatin-related protein/follistatin-like 1 evokes an innate immune response via CD14 and toll-like receptor 4. FEBS Lett. 586:319–324. 2012. View Article : Google Scholar : PubMed/NCBI
22	Zhou X, Xiao X, Huang T, Du C, Wang S, Mo Y, Ma N, Murata M, Li B, Wen W, et al: Epigenetic inactivation of follistatin-like 1 mediates tumor immune evasion in nasopharyngeal carcinoma. Oncotarget. 7:16433–16444. 2016.PubMed/NCBI
23	Liu X, Liu Y, Li X, Zhao J, Geng Y and Ning W: Follistatin like-1 (Fstl1) is required for the normal formation of lung airway and vascular smooth muscle at birth. PLoS One. 12:e01778992017. View Article : Google Scholar : PubMed/NCBI
24	Liu Y, Tan X, Liu W, Chen X, Hou X, Shen D, Ding Y, Yin J, Wang L, Zhang H, et al: Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma. Chin J Cancer. 37:22018. View Article : Google Scholar : PubMed/NCBI
25	Jin X, Nie E, Zhou X, Zeng A, Yu T, Zhi T, Jiang K, Wang Y, Zhang J and You Y: Fstl1 promotes glioma growth through the BMP4/Smad1/5/8 signaling pathway. Cell Physiol Biochem. 44:1616–1628. 2017. View Article : Google Scholar : PubMed/NCBI
26	Ihle JN: The Stat family in cytokine signaling. Curr Opin Cell Biol. 13:211–217. 2001. View Article : Google Scholar : PubMed/NCBI
27	Son DJ, Jung YY, Park MH, Lee HL, Song MJ, Yoo HS, Hwang DY, Han SB and Hong JT: Activated natural killer cells mediate the suppressive effect of interleukin-4 on tumor development via STAT6 activation in an atopic condition melanoma model. Neoplasia. 19:537–548. 2017. View Article : Google Scholar : PubMed/NCBI
28	Jayakumar A and Bothwell ALM: Stat6 promotes intestinal tumorigenesis in a mouse model of adenomatous polyposis by expansion of MDSCs and inhibition of cytotoxic CD8 response. Neoplasia. 19:595–605. 2017. View Article : Google Scholar : PubMed/NCBI
29	Wang H, Huang S, Wu S, Yin S, Tang A and Wen W: Follistatin-like protein-1 upregulates dendritic cell-based immunity in patients with nasopharyngeal carcinoma. J Interferon Cytokine Res. 37:494–502. 2017. View Article : Google Scholar : PubMed/NCBI
30	Hussain S, Kodavanti PP, Marshburg JD, Janoshazi A, Marinakos SM, George M, Rice A, Wiesner MR and Garantziotis S: Decreased uptake and enhanced mitochondrial protection underlie reduced toxicity of nanoceria in human monocyte-derived macrophages. J Biomed Nanotechnol. 12:2139–2150. 2016. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
32	Yadav V, Varshney P, Sultana S, Yadav J and Saini N: Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation. BMC Cancer. 15:5812015. View Article : Google Scholar : PubMed/NCBI
33	Miyake T, Miyake T, Sakaguchi M, Nankai H, Nakazawa T and Morishita R: Prevention of asthma exacerbation in a mouse model by simultaneous inhibition of NF-κB and STAT6 activation using a chimeric decoy strategy. Mol Ther Nucleic Acids. 10:159–169. 2018. View Article : Google Scholar : PubMed/NCBI
34	Mimura K, The JL, Okayama H, Shiraishi K, Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, et al: PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 109:43–53. 2018. View Article : Google Scholar : PubMed/NCBI
35	Shimasaki S, Koga M, Esch F, Cooksey K, Mercado M, Koba A, Ueno N, Ying SY, Ling N and Guillemin R: Primary structure of the human follistatin precursor and its genomic organization. Proc Natl Acad Sci USA. 85:4218–4222. 1988. View Article : Google Scholar : PubMed/NCBI
36	Ni X, Cao X, Wu Y and Wu J: FSTL1 suppresses tumor cell proliferation, invasion and survival in non-small cell lung cancer. Oncol Rep. 39:13–20. 2018.PubMed/NCBI
37	Su S, Parris AB, Grossman G, Mohler JL, Wang Z and Wilson EM: Up-regulation of follistatin-like 1 by the androgen receptor and melanoma antigen-A11 in prostate cancer. Prostate. 77:505–516. 2017. View Article : Google Scholar : PubMed/NCBI
38	Hirsch R and Wilson DC: Follistatin-like protein-1 as a biomarker for inflammatory disorders. US Patent 8,741,584. Filed February 4 2013; issued June 2 2014.
39	Binnemars-Postma K, Bansal R, Storm G and Prakash J: Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer. Faseb J. 32:969–978. 2018. View Article : Google Scholar : PubMed/NCBI
40	Pastuszak-Lewandoska D, Domańska-Senderowska D, Kordiak J, Antczak A, Czarnecka KH, Migdalska-Sęk M, Nawrot E, Kiszałkiewicz JM and Brzeziańska-Lasota E: Immunoexpression analysis of selected JAK/STAT pathway molecules in patients with non- small-cell lung cancer. Pol Arch Intern Med. 127:758–764. 2017.PubMed/NCBI
41	Qing T, Yamin Z, Guijie W, Yan J and Zhongyang S: STAT6 silencing induces hepatocellular carcinoma-derived cell apoptosis and growth inhibition by decreasing the RANKL expression. Biomed Pharmacother. 92:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
42	Leon-Cabrera SA, Molina-Guzman E, Delgado-Ramirez YG, Vázquez-Sandoval A, Ledesma-Soto Y, Pérez-Plasencia CG, Chirino YI, Delgado-Buenrostro NL, Rodriguez-Sosa M, Vaca-Paniagua F, et al: Lack of STAT6 attenuates inflammation and drives protection against early steps of colitis-associated colon cancer. Cancer Immunol Res. 5:385–396. 2017. View Article : Google Scholar : PubMed/NCBI
43	Lu G, Shi W and Zheng H: Inhibition of STAT6/anoctamin-1 activation suppresses proliferation and invasion of gastric cancer cells. Cancer Biother Radiopharm. 33:3–7. 2018. View Article : Google Scholar : PubMed/NCBI